|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:XPR1-MR1 (FusionGDB2 ID:99061) |
Fusion Gene Summary for XPR1-MR1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: XPR1-MR1 | Fusion gene ID: 99061 | Hgene | Tgene | Gene symbol | XPR1 | MR1 | Gene ID | 9213 | 25953 |
| Gene name | xenotropic and polytropic retrovirus receptor 1 | PNKD metallo-beta-lactamase domain containing | |
| Synonyms | IBGC6|SLC53A1|SYG1|X3 | BRP17|DYT8|FKSG19|FPD1|KIPP1184|MR-1|MR-1S|MR1|PDC|PKND1|PNKD1|R1|TAHCCP2 | |
| Cytomap | 1q25.3 | 2q35 | |
| Type of gene | protein-coding | protein-coding | |
| Description | xenotropic and polytropic retrovirus receptor 1X-receptorprotein SYG1 homologsolute carrier family 53 (phosphate exporter), member 1xenotropic and polytropic murine leukemia virus receptor X3 | probable hydrolase PNKDPNKD, MBL domain containingbrain protein 17myofibrillogenesis regulator 1trans-activated by hepatitis C virus core protein 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | Q95460 | |
| Ensembl transtripts involved in fusion gene | ENST00000367590, ENST00000367589, ENST00000467345, | ENST00000434571, ENST00000367579, ENST00000282990, ENST00000367580, ENST00000438435, | |
| Fusion gene scores | * DoF score | 24 X 7 X 12=2016 | 3 X 4 X 2=24 |
| # samples | 27 | 4 | |
| ** MAII score | log2(27/2016*10)=-2.90046432644909 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/24*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: XPR1 [Title/Abstract] AND MR1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | XPR1(180601406)-MR1(181019147), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | XPR1-MR1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. XPR1-MR1 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene breakpoints across XPR1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across MR1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | LUSC | TCGA-33-AASL-01A | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| ChimerDB4 | LUSC | TCGA-33-AASL | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
Top |
Fusion Gene ORF analysis for XPR1-MR1 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000367590 | ENST00000434571 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-intron | ENST00000367590 | ENST00000367579 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-intron | ENST00000367590 | ENST00000282990 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-intron | ENST00000367590 | ENST00000367580 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-3UTR | ENST00000367590 | ENST00000438435 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| Frame-shift | ENST00000367589 | ENST00000434571 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-intron | ENST00000367589 | ENST00000367579 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-intron | ENST00000367589 | ENST00000282990 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-intron | ENST00000367589 | ENST00000367580 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| 5CDS-3UTR | ENST00000367589 | ENST00000438435 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| intron-3CDS | ENST00000467345 | ENST00000434571 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| intron-intron | ENST00000467345 | ENST00000367579 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| intron-intron | ENST00000467345 | ENST00000282990 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| intron-intron | ENST00000467345 | ENST00000367580 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| intron-3UTR | ENST00000467345 | ENST00000438435 | XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019147 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for XPR1-MR1 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019146 | + | 1.08E-06 | 0.9999989 |
| XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019146 | + | 1.08E-06 | 0.9999989 |
| XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019146 | + | 1.08E-06 | 0.9999989 |
| XPR1 | chr1 | 180601406 | + | MR1 | chr1 | 181019146 | + | 1.08E-06 | 0.9999989 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for XPR1-MR1 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | MR1 |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Antigen-presenting molecule specialized in displaying microbial pyrimidine-based metabolites to alpha-beta T cell receptors (TCR) on innate-type mucosal-associated invariant T (MAIT) cells (PubMed:23051753, PubMed:26795251, PubMed:12794138, PubMed:19416870, PubMed:22692454, PubMed:23846752). In complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1-2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers (PubMed:26795251, PubMed:24695216, PubMed:20581831). Signature pyrimidine-based microbial antigens are generated via non-enzymatic condensation of metabolite intermediates of the riboflavin pathway with by-products arising from other metabolic pathways such as glycolysis. Typical potent antigenic metabolites are 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), products of condensation of 5-amino-6-D-ribityaminouracil (5-A-RU) with glyoxal or methylglyoxal by-products, respectively (PubMed:24695216). May present microbial antigens to various TRAV1-2-negative MAIT cell subsets, providing for unique recognition of diverse microbes, including pathogens that do not synthesize riboflavin (PubMed:27527800, PubMed:31113973). Upon antigen recognition, elicits rapid innate-type MAIT cell activation to eliminate pathogenic microbes by directly killing infected cells (PubMed:24695216, PubMed:27527800, PubMed:23846752). During T cell development, drives thymic selection and post-thymic terminal differentiation of MAIT cells in a process dependent on commensal microflora (By similarity). Acts as an immune sensor of cancer cell metabolome (PubMed:31959982). May present a tumor-specific or -associated metabolite essential for cancer cell survival to a pan-cancer TCR consisting of TRAV38.2-DV8*TRAJ31 alpha chain paired with a TRBV25.1*TRBJ2.3 beta chain on a non-MAIT CD8-positive T cell clone (MC.7.G5), triggering T cell-mediated killing of a wide range of cancer cell types (PubMed:31959982). {ECO:0000250|UniProtKB:Q8HWB0, ECO:0000269|PubMed:12794138, ECO:0000269|PubMed:19416870, ECO:0000269|PubMed:20581831, ECO:0000269|PubMed:22692454, ECO:0000269|PubMed:23051753, ECO:0000269|PubMed:23846752, ECO:0000269|PubMed:24695216, ECO:0000269|PubMed:26795251, ECO:0000269|PubMed:27527800, ECO:0000269|PubMed:31113973, ECO:0000269|PubMed:31959982}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for XPR1-MR1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for XPR1-MR1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for XPR1-MR1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | MR1 | Q95460 | DB00098 | Antithymocyte immunoglobulin (rabbit) | Antagonist | Biotech | Approved |
Top |
Related Diseases for XPR1-MR1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | XPR1 | C4225335 | BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 6 | 2 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | XPR1 | C0004782 | Basal Ganglia Diseases | 1 | CTD_human |
| Hgene | XPR1 | C0006663 | Calcinosis | 1 | CTD_human |
| Hgene | XPR1 | C0015371 | Extrapyramidal Disorders | 1 | CTD_human |
| Hgene | XPR1 | C0015624 | Fanconi Syndrome | 1 | GENOMICS_ENGLAND |
| Hgene | XPR1 | C0263628 | Tumoral calcinosis | 1 | CTD_human |
| Hgene | XPR1 | C0393590 | Fahr's syndrome (disorder) | 1 | ORPHANET |
| Hgene | XPR1 | C0521174 | Microcalcification | 1 | CTD_human |
| Hgene | XPR1 | C0750951 | Lenticulostriate Disorders | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies